Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma

D. Ickowicz Schwartz, Y. Gozlan, L. Greenbaum, T. Babushkina, D. J. Katcoff, Z. Malik

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Protoporphyrin IX (PpIX) synthesis by malignant cells is clinically exploited for photodiagnosis and photodynamic therapy following administration of 5-aminolevulinic acid (ALA). The expression and activity of the housekeeping porphobilinogen deaminase (PBGD) was correlated to PpIX synthesis in differentiating B16 melanoma cells. Differentiation was stimulated by two inducers, butyrate and hexamethylene bisacetamide (HMBA), both of which promote the formation of typical melanosomes and melanin, as well as morphological changeover. A marked decrease in total PBGD activity and PpIX synthesis was observed following stimulation by butyrate, while HMBA induced an opposite effect. In contrast, ferrochelatase levels remained unchanged. Photodynamic inactivation of the cells undergoing differentiation was largely dependent on the PpIX accumulation, which was modulated by the two inducers butyrate and HMBA. Fluorescence immunostaining with anti-PBGD antibodies revealed a major PBGD fraction in the nucleus and a minor fraction in the cytosol. This nuclear localisation pattern was confirmed by expression of PBGD fused to green fluorescence protein. We suggest that efficient photodynamic therapy of cancer facilitated by ALA administration can be enhanced using combined therapeutic modalities.

Original languageEnglish
Pages (from-to)1833-1841
Number of pages9
JournalBritish Journal of Cancer
Volume90
Issue number9
DOIs
StatePublished - 4 May 2004

Bibliographical note

Funding Information:
We thank Hemebiothech, Denmark for the generous gift of antihuman PBGD antibodies. We are grateful to Ms Judith Hanania for her skillful help during the course of this study and Professor N Schoenfeld, Dr R Mamet and R Mevasser of the Porphyria Reference Laboratory, The Rabin Center, Israel, for their assistance. The study was supported by a GIF grant no. 052-202.08/98.

Funding

We thank Hemebiothech, Denmark for the generous gift of antihuman PBGD antibodies. We are grateful to Ms Judith Hanania for her skillful help during the course of this study and Professor N Schoenfeld, Dr R Mamet and R Mevasser of the Porphyria Reference Laboratory, The Rabin Center, Israel, for their assistance. The study was supported by a GIF grant no. 052-202.08/98.

FundersFunder number
German-Israeli Foundation for Scientific Research and Development052-202.08/98

    Keywords

    • Differentiation
    • Melanoma
    • Nuclear localisation
    • Photodynamic therapy
    • Porphobilinogen deaminase

    Fingerprint

    Dive into the research topics of 'Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma'. Together they form a unique fingerprint.

    Cite this